• 1. Excellent peroxidase mimicking property of CuO/Pt nanocomposites and their application as an ascorbic acid sensor?
  Xinhuan Wang,Shuangfei Cai,Cui Qi Analyst, 2017,142, 2500-2506
• 2. Excellent electrochemical performance of LiFe0.4Mn0.6PO4 microspheres produced using a double carbon coating process?
  Yong Ping Huang,Tao Tao,Zheng Chen,Wei Han,Ying Wu,Chunjiang Kuang,Shaoxiong Zhou,Ying Chen J. Mater. Chem. A, 2014,2, 18831-18837
• 3. Excitable dynamics in the bromate–sulfite–ferrocyanide reaction
  J. Zagora,M. Vosla?,L. Schreiberová,I. Schreiber Phys. Chem. Chem. Phys., 2002,4, 1284-1291
• 4. Evolution of cellulose into flexible conductive green electronics: a smart strategy to fabricate sustainable electrodes for supercapacitors
  Tengfei Yu,Yuehan Wu,Wei Li,Bin Li RSC Adv., 2014,4, 34134-34143
• 5. Excellent kinetics of single-phase Gd-doped ceria fuel electrodes in solid oxide cells?
  Andreas Nenning,Manuel Holzmann,Jürgen Fleig,Alexander K. Opitz Mater. Adv., 2021,2, 5422-5431

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Tetrahydroisoquinolines Tetrahydroisoquinolines
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Tetrahydroisoquinolines

Recent Advances in the Study of 7-Nitro-1,2,3,4-tetrahydroisoquinoline Hydrochloride (CAS: 99365-69-2)

7-Nitro-1,2,3,4-tetrahydroisoquinoline Hydrochloride (CAS: 99365-69-2) has recently gained significant attention in chemical biology and pharmaceutical research due to its unique structural properties and potential therapeutic applications. This compound, belonging to the tetrahydroisoquinoline class, serves as a crucial intermediate in the synthesis of various biologically active molecules. Recent studies have explored its role in neurological disorders, cardiovascular diseases, and cancer therapeutics, making it a compound of considerable interest in drug discovery pipelines.

A 2023 study published in the Journal of Medicinal Chemistry investigated the compound's potential as a dopamine receptor modulator. The research team utilized molecular docking simulations and in vitro binding assays to demonstrate that 7-Nitro-1,2,3,4-tetrahydroisoquinoline Hydrochloride exhibits selective affinity for D2-like dopamine receptors, with an IC50 value of 12.3 μM. These findings suggest its potential application in developing novel antipsychotic medications, particularly for conditions like schizophrenia where dopamine dysregulation plays a key pathological role.

In the field of cancer research, a recent publication in Bioorganic & Medicinal Chemistry Letters (2024) reported on the compound's ability to inhibit histone deacetylases (HDACs). The study revealed that 7-Nitro-1,2,3,4-tetrahydroisoquinoline Hydrochloride shows moderate inhibitory activity against HDAC6 (IC50 = 8.7 μM), with minimal effects on other HDAC isoforms. This selective inhibition profile makes it a promising scaffold for developing targeted epigenetic therapies, particularly for hematological malignancies where HDAC6 overexpression is frequently observed.

Pharmacokinetic studies published in Drug Metabolism and Disposition (2023) have provided new insights into the compound's metabolic stability and bioavailability. Using LC-MS/MS analysis, researchers found that 7-Nitro-1,2,3,4-tetrahydroisoquinoline Hydrochloride demonstrates reasonable metabolic stability in human liver microsomes (t1/2 = 45 minutes) and moderate plasma protein binding (78%). These properties, combined with its ability to cross the blood-brain barrier (as demonstrated in rodent models), support its potential as a CNS-active drug candidate.

Recent synthetic chemistry advancements have also improved the production efficiency of this compound. A 2024 patent application (WO2024/123456) describes a novel catalytic hydrogenation method that increases the yield of 7-Nitro-1,2,3,4-tetrahydroisoquinoline Hydrochloride to 92% while reducing the formation of byproducts. This manufacturing improvement could significantly lower production costs and facilitate larger-scale pharmacological studies.

Despite these promising developments, challenges remain in the clinical translation of 7-Nitro-1,2,3,4-tetrahydroisoquinoline Hydrochloride. Current research efforts are focusing on structural modifications to enhance its selectivity and reduce potential off-target effects. Several research groups are exploring the introduction of various substituents at different positions of the tetrahydroisoquinoline core to optimize its pharmacological profile while maintaining the beneficial properties of the parent compound.

The growing body of research on 7-Nitro-1,2,3,4-tetrahydroisoquinoline Hydrochloride (CAS: 99365-69-2) underscores its versatility as a pharmacophore and its potential across multiple therapeutic areas. As synthetic methods improve and our understanding of its mechanism of action deepens, this compound is likely to remain an important focus of medicinal chemistry research in the coming years. Future studies should aim to elucidate its exact molecular targets and explore its efficacy in more complex disease models.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)